Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.58 |
| ▸ | LCK | P06239 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609120 | 1.00 | MAPK14 (0.58) | MAPK14LCKSRCKDRKDM4E | |
| SCHEMBL4609373 | 0.94 | MAPK14 (0.56) | MAPK14LCKSRCKDRALDH1A1 | |
| SCHEMBL4609364 | 0.94 | MAPK14 (0.56) | MAPK14LCKSRCKDRALDH1A1 | |
| SCHEMBL4624341 | 0.94 | MAPK14 (0.57) | MAPK14ALDH1A1 | |
| SCHEMBL4624344 | 0.94 | MAPK14 (0.57) | MAPK14ALDH1A1 | |
| SCHEMBL4609947 | 0.93 | MAPK14 (0.59) | MAPK14LCKSRCKDRKDM4E | |
| SCHEMBL4609953 | 0.93 | MAPK14 (0.59) | MAPK14LCKSRCKDRKDM4E | |
| SCHEMBL4655970 | 0.93 | MAPK14 (0.58) | MAPK14LCKSRCKDR | |
| SCHEMBL4655973 | 0.93 | MAPK14 (0.58) | MAPK14LCKSRCKDR | |
| SCHEMBL4607994 | 0.92 | MAPK14 (0.60) | MAPK14LCKSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | claimed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | claimed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | claimed |
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-0795640-B1 | Combination of stabilizers | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1747204-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005105758-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1054031-B1 | Increasing the molecular weight and modification of condensation polymers | CIBA SC HOLDING AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| EP-0819730-B1 | Ozone resistant long-time stabilisers | CIBA SC HOLDING AG (CH) | 2005-04-06 | — | — | EP | disclosed |
| EP-0723990-B1 | Synergistic stabilizing mixture | CIBA SC HOLDING AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| EP-0741163-A1 | Synergistic stabiliser composition | CIBA-GEIGY AG (CH) | 1996-11-06 | — | — | EP | disclosed |
| EP-0729946-A2 | Condensates of butyne-linked hindered amines | CIBA-GEIGY AG (CH) | 1996-09-04 | — | — | EP | disclosed |
| EP-0728806-A1 | Synergistic stabiliser mixture | CIBA-GEIGY AG (CH) | 1996-08-28 | — | — | EP | disclosed |
| EP-0727410-A1 | Bisphenol ester derivatives | CIBA-GEIGY AG (CH) | 1996-08-21 | — | — | EP | disclosed |
| EP-0723990-A1 | Synergistic stabilizing mixture | CIBA-GEIGY AG (CH) | 1996-07-31 | — | — | EP | disclosed |
| EP-0716076-A2 | Bisphenolester derivatives | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
| EP-0711804-A2 | Latent light stabilizers | CIBA-GEIGY AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| EP-0707035-A1 | HALS phosphorinanes as stabilisers | CIBA-GEIGY AG (CH) | 1996-04-17 | — | — | EP | disclosed |
| EP-0685519-A1 | Oligomeric HALS-phosphites and HALS-phosphonites as stabilizers | CIBA-GEIGY AG (CH) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885LCK 1578/4885SRC 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.